Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis
The high use of lenalidomide and DRd in 1L, and high rates of retreatment with lenalidomide and anti-CD38 mAbs in 2L+ indicate a substantial need for new treatment modalities that can be used in 2L+ patients who previously received lenalidomide with/without an anti-CD38 mAb therapy.
Authors
- Chi‐Chang Chen (ORCID: https://orcid.org/0000-0002-7065-9607)
- Yasuhiro Yasutomi (ORCID: https://orcid.org/0009-0000-1853-974X)
- Simon McNamara (ORCID: https://orcid.org/0000-0003-1082-118X)
- Zifan Zhou (ORCID: https://orcid.org/0009-0004-8069-7860)
- Yevgeniy Samyshkin (ORCID: https://orcid.org/0000-0003-3561-5585)
- Wen Shi Lee (ORCID: https://orcid.org/0000-0001-7285-4054)
- Catherine B. McGuiness (ORCID: https://orcid.org/0000-0002-5367-6472)
- Shinsuke Iida (ORCID: https://orcid.org/0000-0002-4951-960X)
- Yi-Chen Chen
- Seok-Won Kim (ORCID: https://orcid.org/0000-0002-9909-5649)
Institutions
- Nagoya City University (JP)
- IQVIA (United States) (US)
- GlaxoSmithKline (Japan) (JP)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-01-23
- DOI
- https://doi.org/10.1371/journal.pone.0315932
- Citations
- 3
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.31
Funders
- GlaxoSmithKline Japan